Hutchmed completes patient enrollment of FRESCO-2 in phase III trial of fruquintinib in metastatic colorectal cancer
Hutchmed (China) Limited (Hutchmed) has announced that it has completed patient enrollment of FRESCO-2, a phase III registration study of fruquintinib, an investigational treatment for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe, Japan and Australia. The enrollment goal was reached on December 2, 2021. Recruitment of 687 patients globally completed in fifteen months, ahead of schedule. FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study and to support global registrations. FRESCO-2 is a randomized, double-blind, placebo-controlled, multicenter trial being conducted in patients with metastatic CRC. The primary endpoint of the study is overall survival (
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
